secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0001213900-23-014358
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma secures $3.175M investment from Lind Partners via convertible note and warrant
--------------------------------------------------------------------------------

- Issued $3.704M secured convertible note to Lind Global Fund II, LP for net proceeds of $3.175M; initial conversion price $1.05/share.
- Also issued warrant to purchase up to 5,291,667 shares at $1.05/share; monthly payments start after 6 months, can be in cash or stock.
- Proceeds to fund Phase II trials for Vitargus (retinal surgery device) and ABV-1505 (ADHD drug).
- Note carries no interest; cash payments include 5% premium; default triggers 120% of outstanding principal.
- Placement agent Allele Capital Partners receives 6% cash fee and warrants for 6% of shares issuable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/0001213900-23-014358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-014358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer